体内递药在基因组治疗中的前景与挑战
The Promise and Challenge of In Vivo Delivery for Genome Therapeutics.
机构信息
Innovative Genomics Institute, University of California , Berkeley, California 94720, United States.
California Institute for Quantitative Biosciences, University of California , Berkeley, California 94720, United States.
出版信息
ACS Chem Biol. 2018 Feb 16;13(2):376-382. doi: 10.1021/acschembio.7b00680. Epub 2017 Oct 19.
Abstract
CRISPR-based genome editing technologies are poised to enable countless new therapies to prevent, treat, or cure diseases with a genetic basis. However, the safe and effective delivery of genome editing enzymes represents a substantial challenge that must be tackled to enable the next generation of genetic therapies. In this Review, we summarize recent progress in developing enzymatic tools to combat genetic disease and examine current efforts to deliver these enzymes to the cells in need of correction. Viral vectors already in use for traditional gene therapy are being applied to enable in vivo CRISPR-based therapeutics, as are emerging technologies such as nanoparticle-based delivery of CRISPR components and direct delivery of preassembled RNA-protein complexes. Success in these areas will allow CRISPR-based genome editing therapeutics to reach their full potential.
摘要
基于 CRISPR 的基因组编辑技术有望为预防、治疗或治愈具有遗传基础的疾病带来无数新疗法。然而，安全有效地递送达基因组编辑酶是一个重大挑战，必须加以解决，才能实现下一代基因治疗。在这篇综述中，我们总结了开发用于治疗遗传疾病的酶工具的最新进展，并探讨了将这些酶递送到需要纠正的细胞中的当前努力。已经用于传统基因治疗的病毒载体正被应用于实现体内基于 CRISPR 的治疗，而新兴技术，如基于纳米颗粒的 CRISPR 成分传递和预组装 RNA-蛋白复合物的直接传递，也正在被应用。在这些领域取得成功将使基于 CRISPR 的基因组编辑治疗发挥其全部潜力。
相似文献
1
The Promise and Challenge of In Vivo Delivery for Genome Therapeutics.体内递药在基因组治疗中的前景与挑战
ACS Chem Biol. 2018 Feb 16;13(2):376-382. doi: 10.1021/acschembio.7b00680. Epub 2017 Oct 19.
2
Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.基于纳米颗粒的 CRISPR/Cas9 基因组编辑治疗药物递送系统。
AAPS J. 2018 Oct 10;20(6):108. doi: 10.1208/s12248-018-0267-9.
3
Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.CRISPR/Cas 在体内基因组编辑中的传递方面。
Acc Chem Res. 2019 Jun 18;52(6):1555-1564. doi: 10.1021/acs.accounts.9b00106. Epub 2019 May 17.
4
Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets.病毒和非病毒系统将基因治疗递送至临床靶标。
Int J Mol Sci. 2024 Jul 4;25(13):7333. doi: 10.3390/ijms25137333.
5
In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.用于治疗性基因编辑的CRISPR/Cas9体内递送：进展与挑战
Bioconjug Chem. 2017 Apr 19;28(4):880-884. doi: 10.1021/acs.bioconjchem.7b00057. Epub 2017 Mar 17.
6
Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.组织特异性递送 CRISPR 治疗药物：非病毒载体的策略和机制。
Int J Mol Sci. 2020 Oct 5;21(19):7353. doi: 10.3390/ijms21197353.
7
Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.基因治疗与 CRISPR/Cas9 渐趋成熟，有望攻克 HIV。
AIDS Rev. 2017 Oct-Dec;19(3):167-172.
8
Biogenic materials for CRISPR delivery and therapeutics.用于 CRISPR 递送和治疗的生物源材料。
Biomater Sci. 2023 May 2;11(9):3016-3033. doi: 10.1039/d2bm02169b.
9
Gene Editing by Ferrying of CRISPR/Cas Ribonucleoprotein Complexes in Enveloped Virus-Derived Particles.通过包膜病毒衍生颗粒中转运 CRISPR/Cas 核糖核蛋白复合物进行基因编辑。
Hum Gene Ther. 2024 Sep;35(17-18):604-616. doi: 10.1089/hum.2024.105. Epub 2024 Aug 27.
10
The delivery challenge: fulfilling the promise of therapeutic genome editing.递送挑战：实现治疗性基因组编辑的承诺。
Nat Biotechnol. 2020 Jul;38(7):845-855. doi: 10.1038/s41587-020-0565-5. Epub 2020 Jun 29.
引用本文的文献
1
Gene therapy of rare diseases as a milestone in medicine - overview of the field and report on initial experiences in Slovenia.罕见病的基因治疗作为医学上的一个里程碑——该领域概述及斯洛文尼亚的初步经验报告
Orphanet J Rare Dis. 2025 Jun 5;20(1):279. doi: 10.1186/s13023-025-03828-8.
2
Autonomous Nucleic Acid and Protein Nanocomputing Agents Engineered to Operate in Living Cells.经设计可在活细胞中运行的自主核酸和蛋白质纳米计算剂。
ACS Nano. 2025 Jan 21;19(2):1865-1883. doi: 10.1021/acsnano.4c13663. Epub 2025 Jan 6.
3
Control of HSV-1 Infection: Directions for the Development of CRISPR/Cas-Based Therapeutics and Diagnostics.单纯疱疹病毒 1 型感染的控制：基于 CRISPR/Cas 的治疗和诊断方法的发展方向。
Int J Mol Sci. 2024 Nov 17;25(22):12346. doi: 10.3390/ijms252212346.
4
Development of artificial transcription factors and their applications in cell reprograming, genetic screen, and disease treatment.人工转录因子的开发及其在细胞重编程、基因筛选和疾病治疗中的应用。
Mol Ther. 2024 Dec 4;32(12):4208-4234. doi: 10.1016/j.ymthe.2024.10.029. Epub 2024 Oct 28.
5
Brainwide silencing of prion protein by AAV-mediated delivery of an engineered compact epigenetic editor.通过 AAV 介导的工程化紧凑表观遗传编辑器，实现全脑朊病毒蛋白沉默。
Science. 2024 Jun 28;384(6703):ado7082. doi: 10.1126/science.ado7082.
6
Machine learning makes magnificent macromolecules for medicine.机器学习为医学创造出了了不起的大分子。
Matter. 2022 Aug 3;5(8):2558-2561. doi: 10.1016/j.matt.2022.07.008. Epub 2022 Aug 5.
7
Engineering self-deliverable ribonucleoproteins for genome editing in the brain.工程自递呈核糖核蛋白用于大脑中的基因组编辑。
Nat Commun. 2024 Feb 26;15(1):1727. doi: 10.1038/s41467-024-45998-2.
8
In vivo human T cell engineering with enveloped delivery vehicles.包膜递送载体在体内的人 T 细胞工程。
Nat Biotechnol. 2024 Nov;42(11):1684-1692. doi: 10.1038/s41587-023-02085-z. Epub 2024 Jan 11.
9
HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing.HIV-1 缓解：加速实现 HIV-1 永久沉默的途径。
Viruses. 2023 Oct 28;15(11):2171. doi: 10.3390/v15112171.
10
Transcriptional linkage analysis with in vivo AAV-Perturb-seq.利用体内 AAV-Perturb-seq 进行转录连锁分析。
Nature. 2023 Oct;622(7982):367-375. doi: 10.1038/s41586-023-06570-y. Epub 2023 Sep 20.
本文引用的文献
1
Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA induces homology-directed DNA repair.纳米颗粒递送Cas9核糖核蛋白和供体DNA可诱导同源定向DNA修复。
Nat Biomed Eng. 2017;1:889-901. doi: 10.1038/s41551-017-0137-2. Epub 2017 Oct 2.
2
Correction of a pathogenic gene mutation in human embryos.人类胚胎中致病基因突变的纠正。
Nature. 2017 Aug 24;548(7668):413-419. doi: 10.1038/nature23305. Epub 2017 Aug 2.
3
In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.PCSK9（前蛋白转化酶枯草杆菌蛋白酶/克新9型）的体内碱基编辑作为基因组编辑的一种治疗替代方法。
Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1741-1747. doi: 10.1161/ATVBAHA.117.309881. Epub 2017 Jul 27.
4
CCR5-edited gene therapies for HIV cure: Closing the door to viral entry.用于治愈艾滋病的CCR5基因编辑疗法：关闭病毒进入之门。
Cytotherapy. 2017 Nov;19(11):1325-1338. doi: 10.1016/j.jcyt.2017.05.013. Epub 2017 Jul 24.
5
CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease.CRISPR/Cas9介导的基因编辑改善了亨廷顿舞蹈病小鼠模型中的神经毒性。
J Clin Invest. 2017 Jun 30;127(7):2719-2724. doi: 10.1172/JCI92087. Epub 2017 Jun 19.
6
CRISPR/Cas9-Mediated Genome Editing Corrects Dystrophin Mutation in Skeletal Muscle Stem Cells in a Mouse Model of Muscle Dystrophy.CRISPR/Cas9介导的基因组编辑纠正了肌肉萎缩症小鼠模型中骨骼肌干细胞的肌营养不良蛋白突变。
Mol Ther Nucleic Acids. 2017 Jun 16;7:31-41. doi: 10.1016/j.omtn.2017.02.007. Epub 2017 Feb 28.
7
CRISPR/Cas9: at the cutting edge of hepatology.CRISPR/Cas9：处于肝病学前沿
Gut. 2017 Jul;66(7):1329-1340. doi: 10.1136/gutjnl-2016-313565. Epub 2017 May 9.
8
Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.利用CRISPR/Cas9推进嵌合抗原受体T细胞疗法
Protein Cell. 2017 Sep;8(9):634-643. doi: 10.1007/s13238-017-0410-x. Epub 2017 Apr 22.
9
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.CRISPR/Cas9 介导的 PD-1 敲除增强了嵌合抗原受体 T 细胞的抗肿瘤疗效。
Sci Rep. 2017 Apr 7;7(1):737. doi: 10.1038/s41598-017-00462-8.
10
Gene Therapy 2017: Progress and Future Directions.《2017年基因治疗：进展与未来方向》
Clin Transl Sci. 2017 Jul;10(4):242-248. doi: 10.1111/cts.12466. Epub 2017 May 23.
Zotero 插件